<DOC>
	<DOCNO>NCT00554086</DOCNO>
	<brief_summary>Multi-centre one year trial patient rise PSA Casodex 50mg daily dose . Casodex dosage escalate 150 mg tablet daily . Treatment continue patient demonstrates clinical benefit one year , PSA progression , toxicity , withdrawal . Treatment continue one year patient demonstrate continued clinical benefit .</brief_summary>
	<brief_title>Open Label , Phase II Trial MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients .</brief_title>
	<detailed_description>The study national , multicentre , open-label , phase II trial . Patients rise PSA MAB bicalutamide 50 mg daily dose escalate MAB 150 mg bicalutamide daily . Subjects receive trial treatment 12 month , disease progression , unacceptable toxicity withdrawal consent . Open label treatment offer thereafter subject demonstrate clinical benefit end one year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>1 . Provision write informed consent . 2 . Men , 18 year age , histologicallyconfirmed prostate cancer 3 . Treatment Zoladex ( goserelin acetate ) great 3 month prior Day 1 4 . Serum testosterone level &lt; 50 ng/ml 5 . Current treatment bicalutamide 50 mg daily . ** 6 . Two consecutive rise PSA nadir value , absolute value late PSA &gt; 2.0 ng/ml . 7 . Highest PSA level great equal 30 ng/ml . 8 . Life expectancy great 1 year 1 . Patients may receive prolonged antiandrogen therapy bicalutamide . Patients receive short term ( 2 month less ) nonsteroidal antiandrogen therapy agent bicalutamide block flare exclude . * 2 . PSA level great 30 ng/ml . 3 . In opinion investigator , evidence severe uncontrolled systemic disease would make undesirable patient participate trial . 4 . Subjects receive prior chemotherapy . 5 . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma superficial transitional cell carcinoma bladder . 6 . Absolute neutrophil count le 1.5 x 109/L platelet less 100 x 109/L . 7 . Serum bilirubin great 1.25 time upper limit reference range ( ULRR ) . 8 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.5 time ULRR . 9 . Serum creatinine great 1.5 time</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>